comparemela.com
  1. Home
  2. Live Updates
  3. Brigitte Keller - Breaking News

Latest Breaking News On - Brigitte keller - Page 1 : comparemela.com

EQS-News: Apogenix AG: Apogenix new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model

EQS-News: Apogenix AG / Key word(s): Scientific publication Apogenix AG: Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model 01.06.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Apogenix’ new CD40 agonist.

United kingdomBaden wübergTim illidgeBrigitte kellerJudith teumerKatja arnoldThomas hoegerMc servicesEuropean medicines agencyDistribution servicesUniversity of manchesterProfessor tim illidgeTumor necrosis factor receptor superfamilySuperfamily agonistsCorporate newsRegulatory announcements

EQS-News: Apogenix AG: Apogenix Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8 2 % in Institutional Database With Asunercept Plus Standard of Care in Newly Diagnosed Glioblastoma Multiforme

EQS-News: Apogenix AG / Key word(s): Study/Study results Apogenix' Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept

Hong kongWei kuo chenMacau generalUnited statesChang gung memorial hospitalTaoyuan xianBaden wübergKatja arnoldHsiu chi chenChia hua chenChia wen huangHong chieh tsaiLinkou chang gungJames xueBrigitte kellerKuo chen wei

EQS-News: VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG

EQS-News: Vakzine Projekt Management GmbH / Key word(s): Study results VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG 25.01.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. VPM ov.

Brigitte kellerGreg plunkettLeander grodeKarsten fischerMc servicesContract research organisationDistribution servicesVakzine projekt management gmbhMemo therapeuticsInvestigational new drug applicationChief executive officerManaging directorProjekt management gmbhCorporate newsRegulatory announcementsEt cest

EQS-News: Vakzine Projekt Management GmbH: VPM oversees clinical trial and translational project management - Positive Phase I data of client Memo Therapeutics AG

EQS-News: Vakzine Projekt Management GmbH / Key word(s): Study results VPM oversees clinical trial and translational project management - Positive Phase I data of client Memo Therapeutics

Brigitte kellerKostenloser wertpapierhandelGreg plunkettLeander grodeKarsten fischerMc servicesContract research organisationDistribution servicesVakzine projekt management gmbhMemo therapeuticsProjekt management gmbhInvestigational new drug applicationChief executive officerManaging directorCorporate newsRegulatory announcements

EQS-News: HepaRegeniX appoints Dr Andreas Busch as Senior Advisor

EQS-News: HepaRegeniX GmbH / Key word(s): Personnel HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor 23.11.2022 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor  Tübingen (Germany), November 2.

Baden wübergUnited kingdomBernard katzMax delbrKatja arnoldLars zenderShaun brownAndreas buschWolfgang albrechtBrigitte kellerAscenion gmbBayer pharmaJohann wolfgang goetheMc servicesUniversity hospital tubingenUniversity in frankfurt

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.